Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (66)	7/20/2006 9:54:11 AM
From: tuck	Respond to of 507

From the PFE PR: >>Exubera, one of the most significant innovations in insulin delivery since the introduction of insulin 85 years ago, represents a profound medical advance that offers patients a novel method of introducing insulin into their systems via the lungs. Long-term efficacy and safety data in both type 1 and type 2 diabetes support Exubera as a valuable new option that, when used as directed, could lead to better blood glucose control and potentially reduce the debilitating and costly complications associated with the disease. Exubera was launched in Germany and Ireland in May 2006. In the U.S., the comprehensive physician and patient education and training program for this landmark innovation in diabetes treatment will begin on July 24, 2006, and will be rolled out in phases. This will include training and demonstration of the proper use of the insulin delivery device and drug for physicians, diabetes educators, and other healthcare professionals. To further support patients and healthcare professionals in the treatment of diabetes and the appropriate use of Exubera, Pfizer is also providing a 24-hour-a-day, 7-day-a-week call center staffed by healthcare professionals. The manufacturing process for Exubera is extremely complex, and working at production capacity at its manufacturing facilities, Pfizer continues to build inventory. "Our education programs and manufacturing preparations are time- consuming, but we are taking the time necessary to do the job right," said Ms. Katen. "We are working to meet not only initial demand for the medicine, but also continued demand from prescription refills. Earlier this week, we held our nationwide launch meeting with our field force. Initial supplies of Exubera will be available across the U.S. beginning in September." << I haven't listened to the CC. NKTR is actually up on the news now. While Pfizer may consider July 24th the launch date, I get the impression most investors equate launch with shipment of first product. Cramer's hedgie network must have been on to some leak (though where that comment about shipment in June came from I can't fathom), hence the weakness up till now, and the recovery on the news. Edit: My goodness, the IV in the options just spiked. The August 15 puts I sold when the stock was almost a point lower? Same price today, almost 2 points away from the strike. Wasn't like that yesterday. Cheers, Tuck

To: Arthur Radley who wrote (66)	7/20/2006 10:22:00 AM
From: tuck	Read Replies (1) \| Respond to of 507

Apparently all that manufacturing for anticipated new scripts is more than expected, TD. Pfizer may be a little late, but it would appear it really believes in Exubera: >>Nektar ups Exubera inhaled insulin revenue view Thu Jul 20, 2006 10:05 AM ET CHICAGO, July 20 (Reuters) - Nektar Therapeutics (NKTR.O: Quote, Profile, Research) on Thursday raised its revenue outlook for Exubera, the first-ever inhaled insulin product it co-developed with Pfizer Inc (PFE.N: Quote, Profile, Research) . Nektar, which makes the inhaler used to deliver the diabetes treatment, raised its revenue outlook for Exubera manufacturing and royalty revenue to a range of $70 million to $90 million, from its prior range of $60 million to $80 million. Nektar said most of the revenue would be generated by manufacturing sales to Pfizer. Pfizer earlier on Wednesday said Exubera would be available across the United States beginning in September. Pfizer will begin a national training and education program for the product this month. Nektar said it will provide a full-year revenue and net loss outlook for 2006 when it announces its second-quarter results.<< Cheers, Tuck